Trials / Completed
CompletedNCT05157594
hPG80 (Circulating Progastrin) as a Blood Biomarker for High-grade Glial Tumors
Pilot Study of hPG80 (Circulating Progastrin) as a Blood Biomarker for High-grade Glial Tumors
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 30 (actual)
- Sponsor
- Centre Jean Perrin · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
PROGLIO is a French mono-centric study with longitudinal follow-up, in which patients with high grade brain tumors will be included. Blood samples will be taken during their therapeutic follow-up to evaluate plasma concentrations of hPG80 (circulating progastrin).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | Blood sample | Evaluation of plasma hPG80 concentrations by fasting blood samples. A total of seven 5 mL blood samples will be taken: Before radiation therapy; at the end of radiation therapy; at cycle 3 of chemotherapy; at cycle 6 of chemotherapy; 3 months after the end of treatment; 6 months after the end of treatment; and 9 months after the end of treatment. |
Timeline
- Start date
- 2022-02-14
- Primary completion
- 2025-08-19
- Completion
- 2025-08-19
- First posted
- 2021-12-15
- Last updated
- 2025-09-22
Locations
1 site across 1 country: France
Source: ClinicalTrials.gov record NCT05157594. Inclusion in this directory is not an endorsement.